Supreme Court clarifies limits of induced infringement liability for skinny labels

Key takeaways from Hikma v. Amarin

As discussed in our earlier update, the case arose from Hikma's launch of a generic version of Amarin's Vascepa (icosapent ethyl) with a section viii statement that carved out Amarin's patented cardiovascular (“CV”) indication (i.e., “skinny label”). Amarin alleged that Hikma nonetheless induced infringement of its CV-indication patents based on the “totality” of Hikma's conduct, including its labeling content (retaining clinical study references with potential bearing on CV use), patient information leaflet language, website descriptions, and press releases describing the product and its market. The Federal Circuit found it “at least plausible” that when considered together, the collected statements could be taken as instructions or encouragement for physicians to prescribe the generic for all the same uses for which Amarin's product was approved.

The Court, however, characterized the Federal Circuit's framing as asking the wrong question. The relevant inquiry, the Court explained, is not how third parties might understand a manufacturer's statements in isolation, but whether those statements plausibly amount to active encouragement of infringement.

The key question is whether a defendant actively encouraged others to infringe through its statements. Inducement need not be express. The issue is not whether a certain chain of events is possible or whether the statements could stimulate infringing acts; the issue is whether the statements are designed to do so. 

The Court found that the totality of Hikma's statements and conduct, “whether viewed together or separately, fail to establish that Hikma took any affirmative steps to encourage infringement.” The decision examined each category of statements on which Amarin relied. In doing so, it placed substantial weight on the fact that many of those statements had “obvious alternative explanations,” such as compliance with FDA's “duty of sameness” for generic labeling or adherence to standard industry practice. For example, Hikma's statements describing its product as “AB” rated or the “generic equivalent” of Vascepa were not evidence of a desire to induce infringement. The Court described these representations as standard industry practice and consistent with the law.

Equally important is the Court's rejection of theories grounded in omission. Amarin emphasized that Hikma failed to highlight the limited scope of its approval and omitted “Limitation of Use” language regarding the patented use. The Court, however, was clear that “Amarin may not rely on ‘mere omissions, inactions, or nonfeasance' to allege active inducement.” The Court held that patient leaflets referencing cardiovascular conditions, website descriptions of therapeutic categories, or press releases including aggregate sales figures were all characterized as too attenuated and speculative to plausibly support liability.

Looking ahead

Ultimately, the Court's articulation of the pleading standard signals that many inducement claims will face renewed scrutiny at the motion to dismiss stage. Allegations based solely on generalized assumptions about prescribing practices or the effects of automatic generic substitution are unlikely to suffice. But the decision is not a wholesale retreat from inducement liability in the skinny-label context. The Court explicitly declined to require that inducement be “express,” acknowledging that liability may arise from implicit yet sufficiently clear forms of encouragement. Accordingly, claims remain viable where a generic manufacturer's labeling, promotional statements, or other communications can plausibly be understood as directing users toward the patented indication. The practical effect of the decision is therefore a narrowing of inducement theories, not the broad safe harbor for FDA-compliant labeling that generic manufacturers had sought. 

Authored by Gary Veron, Howard Levine, Jennifer Swan, Jason Conaty, and Bryan Walsh.